{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:19:37Z","timestamp":1787897977892,"version":"build-2784847793"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10120-026-01780-5","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T09:24:57Z","timestamp":1784021097000},"page":"960-971","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Germline whole-exome sequencing identifies CTNND1 as a candidate gene for hereditary gastric cancer in a large Brazilian cohort"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6193-2118","authenticated-orcid":false,"given":"Deivid Calebe","family":"de Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thaliane","family":"Buranello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario Tenorio Tavares","family":"Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janina Pontes","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna Napolitano Pereira","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Olandoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schlesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Paulo","family":"Kitajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo Vilela","family":"Viana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Isabel","family":"Achatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"1780_CR1","unstructured":"Instituto Nacional de C\u00e2ncer (INCA). Cancer incidence in Brazil: 2026 estimates. Rio de Janeiro: INCA; 2026. Available from: https:\/\/ninho.inca.gov.br\/jspui\/handle\/123456789\/17914."},{"key":"1780_CR2","unstructured":"Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. Global cancer observatory: cancer today. Lyon: International agency for research on cancer; 2024. Available from: https:\/\/gco.iarc.who.int\/today."},{"key":"1780_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21114012","author":"J Machlowska","year":"2020","unstructured":"Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21114012.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1780_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1001\/jamaoncol.2014.168","volume":"1","author":"S Hansford","year":"2015","unstructured":"Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol. 2015;1(1):23\u201332. https:\/\/doi.org\/10.1001\/jamaoncol.2014.168.","journal-title":"JAMA Oncol"},{"issue":"9","key":"1780_CR5","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/jamaoncol.2019.1208","volume":"5","author":"ME Roberts","year":"2019","unstructured":"Roberts ME, Ranola JMO, Marshall ML, Susswein LR, Graceffo S, Bohnert K, et al. Comparison of CDH1 penetrance estimates in clinically ascertained families vs families ascertained for multiple gastric cancers. JAMA Oncol. 2019;5(9):1325\u201331. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1208.","journal-title":"JAMA Oncol"},{"issue":"12","key":"1780_CR6","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1136\/jmedgenet-2019-105991","volume":"56","author":"RM Xicola","year":"2019","unstructured":"Xicola RM, Li S, Rodriguez N, Reinecke P, Karam R, Speare V, et al. Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria. J Med Genet. 2019;56(12):838\u201343. https:\/\/doi.org\/10.1136\/jmedgenet-2019-105991.","journal-title":"J Med Genet"},{"issue":"9","key":"1780_CR7","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2024.10852","volume":"332","author":"CE Ryan","year":"2024","unstructured":"Ryan CE, Fasaye GA, Gallanis AF, Gamble LA, McClelland PH, Duemler A, et al. Germline CDH1 variants and lifetime cancer risk. JAMA. 2024;332(9):722\u20139. https:\/\/doi.org\/10.1001\/jama.2024.10852.","journal-title":"JAMA"},{"issue":"4","key":"1780_CR8","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/path.4152","volume":"229","author":"IJ Majewski","year":"2013","unstructured":"Majewski IJ, Kluijt I, Cats A, Scerri TS, de Jong D, Kluin RJC, et al. An \u03b1-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. J Pathol. 2013;229(4):621\u20139. https:\/\/doi.org\/10.1002\/path.4152.","journal-title":"J Pathol"},{"issue":"10","key":"1780_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2021.104316","volume":"64","author":"S Lobo","year":"2021","unstructured":"Lobo S, Benusiglio PR, Coulet F, Boussemart L, Golmard L, Spier I, et al. Cancer predisposition and germline CTNNA1 variants. Eur J Med Genet. 2021;64(10):104316. https:\/\/doi.org\/10.1016\/j.ejmg.2021.104316.","journal-title":"Eur J Med Genet"},{"issue":"5","key":"1780_CR10","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41436-020-0753-1","volume":"22","author":"DF Clark","year":"2020","unstructured":"Clark DF, Michalski ST, Tondon R, Nehoray B, Ebrahimzadeh J, Hughes SK, et al. Loss-of-function variants in CTNNA1 detected on multigene panel testing in individuals with gastric or breast cancer. Genet Med. 2020;22(5):840\u20136. https:\/\/doi.org\/10.1038\/s41436-020-0753-1.","journal-title":"Genet Med"},{"issue":"12","key":"1780_CR11","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1136\/jmg-2022-108740","volume":"59","author":"M Coudert","year":"2022","unstructured":"Coudert M, Drouet Y, Delhomelle H, Svrcek M, Benusiglio PR, Coulet F, et al. First estimates of diffuse gastric cancer risks for carriers of CTNNA1 germline pathogenic variants. J Med Genet. 2022;59(12):1189\u201395. https:\/\/doi.org\/10.1136\/jmg-2022-108740.","journal-title":"J Med Genet"},{"issue":"5","key":"1780_CR12","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1136\/gutjnl-2024-334601","volume":"75","author":"S Lobo","year":"2026","unstructured":"Lobo S, Dias A, Pedro AM, Ferreira M, Pinto-Oliveira A, S\u00e3o Jos\u00e9 C, et al. Hereditary diffuse gastric cancer spectrum associated with germline CTNNA1 loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls. Gut. 2026;75(5):872\u201385. https:\/\/doi.org\/10.1136\/gutjnl-2024-334601.","journal-title":"Gut"},{"issue":"1","key":"1780_CR13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.giec.2021.08.004","volume":"32","author":"W Kim","year":"2022","unstructured":"Kim W, Kidambi T, Lin J, Idos G. Genetic syndromes associated with gastric cancer. Gastrointest Endosc Clin N Am. 2022;32(1):147\u201362. https:\/\/doi.org\/10.1016\/j.giec.2021.08.004.","journal-title":"Gastrointest Endosc Clin N Am"},{"issue":"5","key":"1780_CR14","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.ajhg.2016.03.001","volume":"98","author":"J Li","year":"2016","unstructured":"Li J, Woods SL, Healey S, Beesley J, Chen X, Lee JS, et al. Point mutations in exon 1B of APC reveal gastric adenocarcinoma and proximal polyposis of the stomach as a familial adenomatous polyposis variant. Am J Hum Genet. 2016;98(5):830\u201342. https:\/\/doi.org\/10.1016\/j.ajhg.2016.03.001.","journal-title":"Am J Hum Genet"},{"key":"1780_CR15","doi-asserted-by":"publisher","first-page":"100982","DOI":"10.1016\/j.lana.2024.100982","volume":"42","author":"PAF Galante","year":"2025","unstructured":"Galante PAF, Guardia GDA, Pisani J, Sandoval RL, Barros-Filho MC, Gifoni ACLVC, et al. Personalized screening strategies for TP53 R337H carriers: a retrospective cohort study of tumor spectrum in Li-Fraumeni syndrome adult carriers. Lancet Reg Health Am. 2025;42:100982. https:\/\/doi.org\/10.1016\/j.lana.2024.100982.","journal-title":"Lancet Reg Health Am."},{"issue":"7","key":"1780_CR16","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/GIM.0b013e31821628b6","volume":"13","author":"S Masciari","year":"2011","unstructured":"Masciari S, Dewanwala A, Stoffel EM, Lauwers GY, Zheng H, Achatz MI, et al. Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med. 2011;13(7):651\u20137. https:\/\/doi.org\/10.1097\/GIM.0b013e31821628b6.","journal-title":"Genet Med"},{"issue":"1\u20132","key":"1780_CR17","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.canlet.2005.12.039","volume":"245","author":"MIW Achatz","year":"2007","unstructured":"Achatz MIW, Olivier M, Calvez FL, Martel-Planche G, Lopes A, Rossi BM, et al. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett. 2007;245(1\u20132):96\u2013102. https:\/\/doi.org\/10.1016\/j.canlet.2005.12.039.","journal-title":"Cancer Lett"},{"issue":"12","key":"1780_CR18","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S2468-1253(18)30237-1","volume":"3","author":"PC Lott","year":"2018","unstructured":"Lott PC, Carvajal-Carmona LG. Resolving gastric cancer aetiology: an update in genetic predisposition. Lancet Gastroenterol Hepatol. 2018;3(12):874\u201383. https:\/\/doi.org\/10.1016\/S2468-1253(18)30237-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"1780_CR19","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1016\/S1470-2045(14)71016-2","volume":"16","author":"C Oliveira","year":"2015","unstructured":"Oliveira C, Pinheiro H, Figueiredo J, Seruca R, Carneiro F. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol. 2015;16(2):e60-70. https:\/\/doi.org\/10.1016\/S1470-2045(14)71016-2.","journal-title":"Lancet Oncol"},{"key":"1780_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01421","volume":"9","author":"W Luo","year":"2018","unstructured":"Luo W, Fedda F, Lynch P, Tan D. CDH1 gene and hereditary diffuse gastric cancer syndrome: molecular and histological alterations and implications for diagnosis and treatment. Front Pharmacol. 2018;9:1421. https:\/\/doi.org\/10.3389\/fphar.2018.01421.","journal-title":"Front Pharmacol"},{"key":"1780_CR21","doi-asserted-by":"publisher","DOI":"10.21037\/tgh.2019.07.02","author":"TP Slavin","year":"2019","unstructured":"Slavin TP, Weitzel JN, Neuhausen SL, Schrader KA, Oliveira C, Karam R. Genetics of gastric cancer: what do we know about the genetic risks? Transl Gastroenterol Hepatol. 2019. https:\/\/doi.org\/10.21037\/tgh.2019.07.02.","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"3","key":"1780_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22031310","volume":"22","author":"C Herrera-Pariente","year":"2021","unstructured":"Herrera-Pariente C, Cap\u00f3-Garc\u00eda R, D\u00edaz-Gay M, Carballal S, Mu\u00f1oz J, Llach J, et al. Identification of new genes involved in germline predisposition to early-onset gastric cancer. Int J Mol Sci. 2021;22(3):1310. https:\/\/doi.org\/10.3390\/ijms22031310.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1780_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2021.104401","volume":"65","author":"J Garcia-Pelaez","year":"2022","unstructured":"Garcia-Pelaez J, Barbosa-Matos R, S\u00e3o Jos\u00e9 C, Sousa S, Gullo I, Hoogerbrugge N, et al. Gastric cancer genetic predisposition and clinical presentations: established heritable causes and potential candidate genes. Eur J Med Genet. 2022;65(1):104401. https:\/\/doi.org\/10.1016\/j.ejmg.2021.104401.","journal-title":"Eur J Med Genet"},{"issue":"5","key":"1780_CR24","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201324. https:\/\/doi.org\/10.1038\/gim.2015.30.","journal-title":"Genet Med"},{"issue":"11","key":"1780_CR25","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1002\/humu.23645","volume":"39","author":"EA Rivera-Mu\u00f1oz","year":"2018","unstructured":"Rivera-Mu\u00f1oz EA, Milko LV, Harrison SM, Azzariti DR, Kurtz CL, Lee K, et al. ClinGen variant curation expert panel experiences and standardized processes for disease and gene-level specification of the ACMG\/AMP guidelines for sequence variant interpretation. Hum Mutat. 2018;39(11):1614\u201322. https:\/\/doi.org\/10.1002\/humu.23645.","journal-title":"Hum Mutat"},{"key":"1780_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30219-9","author":"VR Blair","year":"2020","unstructured":"Blair VR, McLeod M, Carneiro F, Coit DG, D\u2019Addario JL, van Dieren JM, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol. 2020. https:\/\/doi.org\/10.1016\/S1470-2045(20)30219-9.","journal-title":"Lancet Oncol"},{"key":"1780_CR27","unstructured":"National Comprehensive Cancer Network. Genetic\/familial high-risk assessment: breast, ovarian, pancreatic, and prostate (version 3.2026). NCCN clinical practice guidelines in oncology. 2026. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bopp.pdf."},{"key":"1780_CR28","unstructured":"National Comprehensive Cancer Network. Genetic\/familial high-risk assessment: colorectal, endometrial, esophageal, and gastric (version 1.2026) . NCCN clinical practice guidelines in oncology. 2026. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_ceeg.pdf."},{"issue":"6","key":"1780_CR29","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1001\/jamaoncol.2022.0476","volume":"8","author":"Y Momozawa","year":"2022","unstructured":"Momozawa Y, Sasai R, Usui Y, Shiraishi K, Iwasaki Y, Taniyama Y, et al. Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants. JAMA Oncol. 2022;8(6):871\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2022.0476.","journal-title":"JAMA Oncol"},{"issue":"7","key":"1780_CR30","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S2468-1253(18)30079-7","volume":"3","author":"E Fewings","year":"2018","unstructured":"Fewings E, Larionov A, Redman J, Goldgraben MA, Scarth J, Richardson S, et al. Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. Lancet Gastroenterol Hepatol. 2018;3(7):489\u201398. https:\/\/doi.org\/10.1016\/S2468-1253(18)30079-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1780_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30120-1","author":"LG Carvajal-Carmona","year":"2018","unstructured":"Carvajal-Carmona LG. PALB2 as a familial gastric cancer gene: is the wait over? Lancet Gastroenterol Hepatol. 2018. https:\/\/doi.org\/10.1016\/S2468-1253(18)30120-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"14","key":"1780_CR32","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1200\/JCO.21.02112","volume":"40","author":"S Li","year":"2022","unstructured":"Li S, Silvestri V, Leslie G, Rebbeck TR, Neuhausen SL, Hopper JL, et al. Cancer risks associated with BRCA1 and BRCA2 pathogenic variants. J Clin Oncol. 2022;40(14):1529\u201341. https:\/\/doi.org\/10.1200\/JCO.21.02112.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"1780_CR33","doi-asserted-by":"publisher","first-page":"A10","DOI":"10.1186\/1897-4287-10-S1-A10","volume":"10","author":"U Teodorczyk","year":"2012","unstructured":"Teodorczyk U, Cybulski C, Jakubowska A, Starzy\u0144ska T, \u0141awniczak M, Ferenc K, et al. The CHEK 2 gene mutations and the risk of gastric cancer. Hered Cancer Clin Pract. 2012;10(Suppl 1):A10. https:\/\/doi.org\/10.1186\/1897-4287-10-S1-A10.","journal-title":"Hered Cancer Clin Pract"},{"issue":"1","key":"1780_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.23193","volume":"63","author":"A Bouras","year":"2024","unstructured":"Bouras A, Lefol C, Ruano E, Grand-Masson C, Wang Q. PMS2 or PMS2CL? Characterization of variants detected in the 3\u2019 of the PMS2 gene. Genes Chromosomes Cancer. 2024;63(1):e23193. https:\/\/doi.org\/10.1002\/gcc.23193.","journal-title":"Genes Chromosomes Cancer"},{"issue":"8","key":"1780_CR35","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41576-023-00598-6","volume":"24","author":"KJ Gaulton","year":"2023","unstructured":"Gaulton KJ, Preissl S, Ren B. Interpreting non-coding disease-associated human variants using single-cell epigenomics. Nat Rev Genet. 2023;24(8):516\u201334. https:\/\/doi.org\/10.1038\/s41576-023-00598-6.","journal-title":"Nat Rev Genet"},{"issue":"12","key":"1780_CR36","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/j.ajhg.2022.10.013","volume":"109","author":"V Pejaver","year":"2022","unstructured":"Pejaver V, Byrne AB, Feng BJ, Pagel KA, Mooney SD, Karchin R, et al. Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3\/BP4 criteria. Am J Hum Genet. 2022;109(12):2163\u201377. https:\/\/doi.org\/10.1016\/j.ajhg.2022.10.013.","journal-title":"Am J Hum Genet"},{"issue":"7","key":"1780_CR37","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.ajhg.2023.06.002","volume":"110","author":"LC Walker","year":"2023","unstructured":"Walker LC, Hoya M, Wiggins GAR, Lindy A, Vincent LM, Parsons MT, et al. Using the ACMG\/AMP framework to capture evidence related to predicted and observed impact on splicing: recommendations from the ClinGen SVI Splicing Subgroup. Am J Hum Genet. 2023;110(7):1046\u201367. https:\/\/doi.org\/10.1016\/j.ajhg.2023.06.002.","journal-title":"Am J Hum Genet"},{"key":"1780_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2017.01.011","author":"LJ Jennings","year":"2017","unstructured":"Jennings LJ, Arcila ME, Corless C, Kamel-Reid S, Lubin IM, Pfeifer J, et al. Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the association for molecular pathology and college of american pathologists. J Mol Diagn. 2017. https:\/\/doi.org\/10.1016\/j.jmoldx.2017.01.011.","journal-title":"J Mol Diagn"},{"issue":"5","key":"1780_CR39","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/humu.24183","volume":"42","author":"AL Davidson","year":"2021","unstructured":"Davidson AL, Leonard C, Koufariotis LT, Parsons MT, Hollway GE, Pearson JV, et al. Considerations for using population frequency data in germline variant interpretation: cancer syndrome genes as a model. Hum Mutat. 2021;42(5):530\u20136. https:\/\/doi.org\/10.1002\/humu.24183.","journal-title":"Hum Mutat"},{"issue":"12","key":"1780_CR40","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/s41576-023-00668-9","volume":"24","author":"K Minton","year":"2023","unstructured":"Minton K. Predicting variant pathogenicity with AlphaMissense. Nat Rev Genet. 2023;24(12):804. https:\/\/doi.org\/10.1038\/s41576-023-00668-9.","journal-title":"Nat Rev Genet"},{"issue":"8","key":"1780_CR41","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/s41431-024-01638-3","volume":"32","author":"NS Andhika","year":"2024","unstructured":"Andhika NS, Biswas S, Hardcastle C, Green DJ, Ramsden SC, Birney E, et al. Using computational approaches to enhance the interpretation of missense variants in the PAX6 gene. Eur J Hum Genet. 2024;32(8):1005\u201313. https:\/\/doi.org\/10.1038\/s41431-024-01638-3.","journal-title":"Eur J Hum Genet"},{"issue":"12","key":"1780_CR42","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.1111\/epi.18155","volume":"65","author":"L Montanucci","year":"2024","unstructured":"Montanucci L, Br\u00fcnger T, Bo\u00dfelmann CM, Ivaniuk A, P\u00e9rez-Palma E, Lhatoo S, et al. Evaluating novel in silico tools for accurate pathogenicity classification in epilepsy-associated genetic missense variants. Epilepsia. 2024;65(12):3655\u201363. https:\/\/doi.org\/10.1111\/epi.18155.","journal-title":"Epilepsia"},{"issue":"19","key":"1780_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17193209","volume":"17","author":"C Pardo","year":"2025","unstructured":"Pardo C, Luzko I, Castillo-Iturra J, Cant\u00fa-Germano E, Moreira L. Familial non-hereditary gastric cancer: diagnosis, management, molecular characteristics and future perspective. Cancers (Basel). 2025;17(19):3209. https:\/\/doi.org\/10.3390\/cancers17193209.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"1780_CR44","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/jnci\/djae184","volume":"116","author":"WD Foulkes","year":"2024","unstructured":"Foulkes WD, Polak P. Probing the relevance of BRCA1 and BRCA2 germline pathogenic variants beyond breast and ovarian cancer. J Natl Cancer Inst. 2024;116(12):1871\u20134. https:\/\/doi.org\/10.1093\/jnci\/djae184.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1780_CR45","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1053\/j.gastro.2020.03.086","volume":"159","author":"SS Kupfer","year":"2020","unstructured":"Kupfer SS, Gupta S, Weitzel JN, Samadder J. AGA clinical practice update on colorectal and pancreatic cancer risk and screening in BRCA1 and BRCA2 carriers: commentary. Gastroenterology. 2020;159(2):760\u20134. https:\/\/doi.org\/10.1053\/j.gastro.2020.03.086.","journal-title":"Gastroenterology"},{"issue":"1","key":"1780_CR46","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(22)00700-8","volume":"24","author":"CYC Lee","year":"2023","unstructured":"Lee CYC, Olivier A, Honing J, Lydon AM, Richardson S, O\u2019Donovan M, et al. Endoscopic surveillance with systematic random biopsy for the early diagnosis of hereditary diffuse gastric cancer: a prospective 16-year longitudinal cohort study. Lancet Oncol. 2023;24(1):107\u201316. https:\/\/doi.org\/10.1016\/S1470-2045(22)00700-8.","journal-title":"Lancet Oncol"},{"key":"1780_CR47","doi-asserted-by":"publisher","first-page":"e2245836","DOI":"10.1001\/jamanetworkopen.2022.45836","volume":"12","author":"ZX Liu","year":"2022","unstructured":"Liu ZX, Zhang XL, Zhao Q, Chen Y, Sheng H, He CY, et al. Whole-exome sequencing among Chinese patients with hereditary diffuse gastric cancer. JAMA Netw Open. 2022;12:e2245836. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.45836.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"1780_CR48","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1007\/s00432-021-03775-4","volume":"148","author":"Z Pan","year":"2022","unstructured":"Pan Z, Fu Z, Luo C, Bao Y, Wang M, Cao W, et al. CDH1 germline mutations in a Chinese cohort with hereditary diffuse gastric cancer. J Cancer Res Clin Oncol. 2022;148(8):2145\u201351. https:\/\/doi.org\/10.1007\/s00432-021-03775-4.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"1780_CR49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1006\/geno.1998.5325","volume":"50","author":"A Keirsebilck","year":"1998","unstructured":"Keirsebilck A, Bonn\u00e9 S, Staes K, van Hengel J, Nollet F, Reynolds A, et al. Molecular cloning of the human p120ctn catenin gene (CTNND1): expression of multiple alternatively spliced isoforms. Genomics. 1998;50(2):129\u201346. https:\/\/doi.org\/10.1006\/geno.1998.5325.","journal-title":"Genomics"},{"issue":"1","key":"1780_CR50","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.cell.2010.01.017","volume":"141","author":"N Ishiyama","year":"2010","unstructured":"Ishiyama N, Lee SH, Liu S, Li GY, Smith MJ, Reichardt LF, et al. Dynamic and static interactions between p120 catenin and E-cadherin regulate the stability of cell-cell adhesion. Cell. 2010;141(1):117\u201328. https:\/\/doi.org\/10.1016\/j.cell.2010.01.017.","journal-title":"Cell"},{"issue":"17","key":"1780_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174313","volume":"15","author":"J Guerra","year":"2023","unstructured":"Guerra J, Pinto C, Pinto P, Pinheiro M, Santos C, Peixoto A, et al. Frequency of CDH1, CTNNA1 and CTNND1 germline variants in families with diffuse and mixed gastric cancer. Cancers (Basel). 2023;15(17):4313. https:\/\/doi.org\/10.3390\/cancers15174313.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"1780_CR52","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s10120-024-01504-7","volume":"27","author":"C Herrera-Pariente","year":"2024","unstructured":"Herrera-Pariente C, Bonjoch L, Mu\u00f1oz J, Fern\u00e0ndez G, Soares de Lima Y, Mahmood R, et al. CTNND1 is involved in germline predisposition to early-onset gastric cancer by affecting cell-to-cell interactions. Gastric Cancer. 2024;27(4):747\u201359. https:\/\/doi.org\/10.1007\/s10120-024-01504-7.","journal-title":"Gastric Cancer"},{"issue":"12","key":"1780_CR53","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1158\/1055-9965.EPI-12-1110","volume":"21","author":"JM Schuetz","year":"2012","unstructured":"Schuetz JM, Leach S, Kaurah P, Jeyes J, Butterfield Y, Huntsman D, et al. Catenin family genes are not commonly mutated in hereditary diffuse gastric cancer. Cancer Epidemiol Biomarkers Prev. 2012;21(12):2272\u20134. https:\/\/doi.org\/10.1158\/1055-9965.EPI-12-1110.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9","key":"1780_CR54","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/gim.2017.11","volume":"19","author":"J Ghoumid","year":"2017","unstructured":"Ghoumid J, Stichelbout M, Jourdain AS, Frenois F, Lejeune-Dumoulin S, Alex-Cordier MP, et al. Blepharocheilodontic syndrome is a CDH1 pathway-related disorder due to mutations in CDH1 and CTNND1. Genet Med. 2017;19(9):1013\u201321. https:\/\/doi.org\/10.1038\/gim.2017.11.","journal-title":"Genet Med"},{"issue":"2","key":"1780_CR55","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/ng.3474","volume":"48","author":"NTM Saksens","year":"2016","unstructured":"Saksens NTM, Krebs MP, Schoenmaker-Koller FE, Hicks W, Yu M, Shi L, et al. Mutations in CTNNA1 cause butterfly-shaped pigment dystrophy and perturbed retinal pigment epithelium integrity. Nat Genet. 2016;48(2):144\u201351. https:\/\/doi.org\/10.1038\/ng.3474.","journal-title":"Nat Genet"},{"issue":"14","key":"1780_CR56","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.158428","volume":"7","author":"M Yang","year":"2022","unstructured":"Yang M, Li S, Huang L, Zhao R, Dai E, Jiang X, et al. CTNND1 variants cause familial exudative vitreoretinopathy through the Wnt\/cadherin axis. JCI Insight. 2022;7(14):e158428. https:\/\/doi.org\/10.1172\/jci.insight.158428.","journal-title":"JCI Insight"},{"issue":"6664","key":"1780_CR57","doi-asserted-by":"publisher","DOI":"10.1126\/science.adg7492","volume":"381","author":"J Cheng","year":"2023","unstructured":"Cheng J, Novati G, Pan J, Bycroft C, \u017demgulyt\u0117 A, Applebaum T, et al. Accurate proteome-wide missense variant effect prediction with AlphaMissense. Science. 2023;381(6664):eadg7492. https:\/\/doi.org\/10.1126\/science.adg7492.","journal-title":"Science"},{"issue":"10","key":"1780_CR58","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(20)30445-9.","journal-title":"Lancet Oncol"},{"issue":"13","key":"1780_CR59","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","volume":"25","author":"L Marcus","year":"2019","unstructured":"Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):3753\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-4070.","journal-title":"Clin Cancer Res"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01780-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-026-01780-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01780-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:53:42Z","timestamp":1787896422000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-026-01780-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1780"],"URL":"https:\/\/doi.org\/10.1007\/s10120-026-01780-5","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}